About Glypican-3
Glypican-3 (GPC3) is a protein
from Homo sapiens identified by UniProt accession
P51654, 580 residues long.
MolForge cross-references it against 0 known binders and
621 disease associations.
Target properties
| Protein name | Glypican-3 |
| UniProt accession | P51654 |
| Gene | GPC3 |
| Organism | Homo sapiens |
| Length | 580 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (621)
Diseases linked to this target (Open Targets).
- Wilms tumor 1 · score 0.71
- Simpson-Golabi-Behmel syndrome · score 0.71
- COVID-19 · score 0.54
- genetic disorder · score 0.46
- kidney neoplasm · score 0.37
- pancreatic ductal adenocarcinoma · score 0.37
- Polydactyly · score 0.37
- pancreatic carcinoma · score 0.37
- bile duct carcinoma · score 0.37
- prostate adenocarcinoma · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51654-F1 | alphafold | PREDICTED | 75.08 | — |
Amino-acid sequence (580 residues)
MAGTVRTACL VVAMLLSLDF PGQAQPPPPP PDATCHQVRS FFQRLQPGLK WVPETPVPGS DLQVCLPKGP TCCSRKMEEK YQLTARLNME QLLQSASMEL KFLIIQNAAV FQEAFEIVVR HAKNYTNAMF KNNYPSLTPQ AFEFVGEFFT DVSLYILGSD INVDDMVNEL FDSLFPVIYT QLMNPGLPDS ALDINECLRG ARRDLKVFGN FPKLIMTQVS KSLQVTRIFL QALNLGIEVI NTTDHLKFSK DCGRMLTRMW YCSYCQGLMM VKPCGGYCNV VMQGCMAGVV EIDKYWREYI LSLEELVNGM YRIYDMENVL LGLFSTIHDS IQYVQKNAGK LTTTIGKLCA HSQQRQYRSA YYPEDLFIDK KVLKVAHVEH EETLSSRRRE LIQKLKSFIS FYSALPGYIC SHSPVAENDT LCWNGQELVE RYSQKAARNG MKNQFNLHEL KMKGPEPVVS QIIDKLKHIN QLLRTMSMPK GRVLDKNLDE EGFESGDCGD DEDECIGGSG DGMIKVKNQL RFLAELAYDL DVDDAPGNSQ QATPKDNEIS TFHNLGNVHS PLKLLTSMAI SVVCFFFLVH
Explore Glypican-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets